Therefore, the differential response to CBP/p300 inhibition between KCN and KCNR are not due to the initial mutational/epigenetic spectrum that gave rise to neuroblastoma in this patient, but likely from subsequent alterations which occurred between the primary and secondary tumours. Here, CREBBP is linked to neoplasm.